Pharmacologic treatment of adolescent and child schizophrenia

Christopher M. Young, Robert L Findling

Research output: Contribution to journalArticle

Abstract

Although relatively rare in childhood, the incidence of schizophrenia increases in adolescence. Compared with adult-onset schizophrenia, there are differences in the response to various psychopharmacologic agents and an urgent need for more clinical treatment trials in child-onset schizophrenia. The history, epidemiology and clinical presentation of early- and very early-onset schizophrenia is reviewed with a focus on the available pharmacologic treatment literature. Information on the older typical antipsychotics, newer atypical antipsychotics and most promising new potential agents, their benefits and pitfalls are summarized. Acute management as well as continuation and maintenance therapy recommendations are made.

Original languageEnglish (US)
Pages (from-to)53-60
Number of pages8
JournalExpert Review of Neurotherapeutics
Volume4
Issue number1
DOIs
StatePublished - Jan 2004
Externally publishedYes

Fingerprint

Schizophrenia
Antipsychotic Agents
Childhood Schizophrenia
Epidemiology
Therapeutics
History
Clinical Trials
Incidence

Keywords

  • Antipsychotics
  • Atypical antipsychotics
  • Child and adolescent schizophrenia

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Pharmacologic treatment of adolescent and child schizophrenia. / Young, Christopher M.; Findling, Robert L.

In: Expert Review of Neurotherapeutics, Vol. 4, No. 1, 01.2004, p. 53-60.

Research output: Contribution to journalArticle

@article{85c5d5c8125c4c318d2c1508a9c62007,
title = "Pharmacologic treatment of adolescent and child schizophrenia",
abstract = "Although relatively rare in childhood, the incidence of schizophrenia increases in adolescence. Compared with adult-onset schizophrenia, there are differences in the response to various psychopharmacologic agents and an urgent need for more clinical treatment trials in child-onset schizophrenia. The history, epidemiology and clinical presentation of early- and very early-onset schizophrenia is reviewed with a focus on the available pharmacologic treatment literature. Information on the older typical antipsychotics, newer atypical antipsychotics and most promising new potential agents, their benefits and pitfalls are summarized. Acute management as well as continuation and maintenance therapy recommendations are made.",
keywords = "Antipsychotics, Atypical antipsychotics, Child and adolescent schizophrenia",
author = "Young, {Christopher M.} and Findling, {Robert L}",
year = "2004",
month = "1",
doi = "10.1586/14737175.4.1.53",
language = "English (US)",
volume = "4",
pages = "53--60",
journal = "Expert Review of Neurotherapeutics",
issn = "1473-7175",
publisher = "Expert Reviews Ltd.",
number = "1",

}

TY - JOUR

T1 - Pharmacologic treatment of adolescent and child schizophrenia

AU - Young, Christopher M.

AU - Findling, Robert L

PY - 2004/1

Y1 - 2004/1

N2 - Although relatively rare in childhood, the incidence of schizophrenia increases in adolescence. Compared with adult-onset schizophrenia, there are differences in the response to various psychopharmacologic agents and an urgent need for more clinical treatment trials in child-onset schizophrenia. The history, epidemiology and clinical presentation of early- and very early-onset schizophrenia is reviewed with a focus on the available pharmacologic treatment literature. Information on the older typical antipsychotics, newer atypical antipsychotics and most promising new potential agents, their benefits and pitfalls are summarized. Acute management as well as continuation and maintenance therapy recommendations are made.

AB - Although relatively rare in childhood, the incidence of schizophrenia increases in adolescence. Compared with adult-onset schizophrenia, there are differences in the response to various psychopharmacologic agents and an urgent need for more clinical treatment trials in child-onset schizophrenia. The history, epidemiology and clinical presentation of early- and very early-onset schizophrenia is reviewed with a focus on the available pharmacologic treatment literature. Information on the older typical antipsychotics, newer atypical antipsychotics and most promising new potential agents, their benefits and pitfalls are summarized. Acute management as well as continuation and maintenance therapy recommendations are made.

KW - Antipsychotics

KW - Atypical antipsychotics

KW - Child and adolescent schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=0345862287&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0345862287&partnerID=8YFLogxK

U2 - 10.1586/14737175.4.1.53

DO - 10.1586/14737175.4.1.53

M3 - Article

C2 - 15853615

AN - SCOPUS:0345862287

VL - 4

SP - 53

EP - 60

JO - Expert Review of Neurotherapeutics

JF - Expert Review of Neurotherapeutics

SN - 1473-7175

IS - 1

ER -